Kornimate/medical-research-clean huggingface dataset:
self-help lifestyle medicine for depression and anxiety

Conditions: Depression, Anxiety

Summary: this study will examine the effects of smartphone-based lifestyle medicine (lm) for alleviating depressive and anxiety symptoms in chinese population. since a range of lifestyle factors are involved in the pathogenesis and progression of depression and anxiety, modifying different lifestyle factors simultaneously, for example, diet, exercise, stress and sleep which are empirically supported by previous reviews, may be effective to reduce depressive and anxiety symptoms. traditional chinese medicine concepts will be integrated into the app to increase the acceptability towards mental health treatment. through this study, we aim to promote evidence-based patient care and to improve help-seeking and access to evidence-based interventions for depression and anxiety.

this study will be a randomized controlled trial on the effects of a culturally adapted self-help smartphone-based lifestyle medicine for reducing depressive and anxiety symptoms in chinese population. prior to all study procedures, eligible participants will be required to complete an online informed consent (with telephone support). with an estimation of 30% withdrawal, around 124 eligible participants will be randomly assigned to either smartphone-based lifestyle medicine (lm group) or the waitlist control group (wl group) in a ratio of 1:1.

Eligibility criteria:
inclusion criteria: * hong kong residents * aged ≥ 18 years * have a patient health questionnaire (phq-9) score ≥ 10 or generalized anxiety disorder 7-item scale (gad-7) ≥ 8 * able to read chinese and type in chinese or english * have an internet-enabled mobile device (ios or android operating system) * are willing to provide informed consent and comply with the trial protocol exclusion criteria: * current involvement in psychotherapy or unstable medication for depression and/or anxiety * beck depression inventory (bdi-ii) item 9 score of at least 2 indicating a current moderate suicidal risk that requires active crisis management (referral information to professional services will be provided to those with serious suicidal risk) * are having unsafe conditions and are not recommended for physical activity or a change in diet by physicians * having major psychiatric, medical or neurocognitive disorders that make participation infeasible or interfere with the adherence to the lifestyle modification

Keywords: depression anxiety lifestyle medicine self-help
does myocardial bridge appear more frequently and diffusely on radial access coronary angiography

Conditions: Myocardial Bridge of Coronary Artery

Summary: although the incidence of myocardial bridge (mb) has been defined in different conventional coronary angiography (cca) studies,the frequency of mb in radial access coronary angiography (raca) is unknown.the aim of this study was to determine the incidence of mb in patients undergoing raca.


Eligibility criteria:
inclusion criteria: * undergoing radial access coronary angiography * have myocardial bridge exclusion criteria: * a history of coronary artery bypass grafting (cabg)

Keywords: myocardial bridge radial access coronary angiography
the long-term effect on oral health using a powered toothbrush in individuals with mild cognitive impairment

Conditions: Oral Health; Quality of Life

Summary: for this study, 213 individuals with mild cognitive impairment were recruited. the study period ran from june 2018 to october 2021. the procedure involved a combined screening and baseline examination, including oral, medical, cognitive, and quality-of-life examinations. re-examinations followed this at 6, 12, and 24 months. the examinations were performed at a university research clinic, and all participants received their usual medical and dental care during the study. at baseline, each participant received a powered toothbrush. participants were carefully instructed on how to operate the powered toothbrush and were asked to brush for at least two minutes in the morning and evening. no restrictions were given against the use of other oral care products. compliance with the powered toothbrush was followed by a participant survey conducted at each examination.. facilitating and improving life by introducing a powered toothbrush as part of oral hygiene may benefit individuals with mci. this study aimed to investigate whether the use of a powered toothbrush could maintain or improve oral health by reducing dental plaque (pi), bleeding on probing (bop), and periodontal pocket depth (ppd)≥4mm in a group of individuals with mci for an observation period of 24 months. furthermore, to study how oral health changes affect qol aspects.


Eligibility criteria:
inclusion criteria: * being 55 years or older * having experienced memory problems in the last six months before inclusion * having a mini-mental state examination score of 20-28 * are not receiving any formal care * having at least ten teeth of their own exclusion criteria: * having a terminal illness with less than three years of expected survival * having another known significant cause of disease explaining cognitive impairment

Keywords: mild cognitive impairment oral health quality of life powered toothbrush
the health for hearts united collaborative

Conditions: Cardiovascular Disease Risk Reduction

Summary: this proposed project will determine the effectiveness of health for hearts united collaborative (hhuc) implementation strategies in relation to process outcomes and reducing cardiovascular disease (cvd) risk in african americans (aas),examining two possible strategies.

this project will determine the effectiveness of hhuc implementation strategies in relation to process outcomes and reducing cvd risk in aas, guided by ecological theory, the consolidated framework for implementation research (cfir), and the reach, effectiveness, adoption, implementation and maintenance (re-aim) framework. the hhuc model currently includes three components: governance structure, annual events, and basic support. the investigators propose adding a fourth component that includes one of two possible implementation strategies: 1) an internal champions (ic)-driven strategy that includes two features (leadership development, culturally-tailored planning approaches) or 2) an external change agent (external professionals \[ep\])-driven strategy without these features. the investigators will pilot and refine the ic and ep-driven implementation strategies using health leaders from four churches in the two-county area by determining feasibility and acceptability. following the pilot, the investigators will use an effectiveness implementation hybrid type 3 design to evaluate the ic and ep implementation strategies in relation to process outcomes. the study will be conducted in a two-county area in north florida, using congregants ((18 years of age and older, n=225) in nine churches: three ic treatment, three ep treatment, and three comparison with delayed comparable activities.

Eligibility criteria:
inclusion criteria: * african american, * 18 years of age and older, * not pregnant in the last six months, * not hospitalized or having a clinically significant medical condition in the past six months exclusion criteria: * not being african american, * under the age of 18, * pregnant in the last six months, * hospitalized or having a clinically significant medical condition in the past six months.
68ga-jh04 pet/ct: dosimetry and biodistribution studies

Conditions: Malignant Neoplasm

Summary: 68ga-jh04 is a novel radiotracer targeting fibroblast activation protein (fap). in this study, we observed the safety, biodistribution, and radiation dosimetry of 68ga-jh04 in patients with different types of cancer.

carcinoma-associated fibroblasts (cafs) are an integral part of the tumor microenvironment, and fibroblast activation protein (fap), as a specific marker of cafs, is overexpressed in more than 90% of epithelial malignant tumors' cafs, with limited expression in normal tissues, making it an appropriate target for various tumors. currently, several tracers targeting fap for diagnostic purposes have been developed, such as 68ga-fapi-04, 68ga-fapi-02, and showed high efficacy in tumor staging and restaging. 68ga-jh04, a novel radiopharmaceutical targeting fap, demostrated high stability in vitro and in vivo, and can accumulate specifically in tumors with high binding affinity, safety, and selectivity in preclinical studies. in this study, the safety, biodistribution, and radiation dosimetry of 68ga-jh04 in patients with different types of cancer were observed to evaluate the dosimetric characteristics of 68ga-jh04.

Eligibility criteria:
inclusion criteria: * various solid tumors with available histopathological findings * signed informed consent exclusion criteria: * pregnant or lactational women * who suffered from severe hepatic and renal insufficiency
improving genetic counseling for patients with spina bifida using next generation sequencing

Conditions: Spina Bifida

Summary: the main objective is to improve genetic counseling in patients with spina bifida, by the characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.


Eligibility criteria:
inclusion criteria: * spina bifida patients (without age restriction), attending the genetic consultation at the national reference centre for spina bifida. these patients gave their written agreement for studying genes which could be involved in spina bifida. exclusion criteria: * patients who refused to give their authorization to perform the sequencing of genes involved in spina bifida on their dna
high pasta vs. low pasta diet in the treatment of obesity

Conditions: Diet Therapy

Summary: to the best of our knowledge, the effect of pasta consumption within a hypocaloric mediterranean diet has only been scarcely explored yet. therefore, a two-parallel group dietary intervention was carried out to investigate if pasta consumption could affect the bmi change in obese patients. the primary outcome was the loss of at leat 8% of the initial body weight in the first 6 months. anthropometric and body composition (from bioelectrical impedance analysis - bia-) measures were collected every month for the first 6 months and after 1 year. in addition, dietary information was collected at baseline and after 3, 6 and 12 months through a 7-day carbohydrate food record and a 24-h food recall. blood samples were collected at baseline and at 6 and 12 months to assess: glucose, insulin, homeostatic model assessment for insulin resistant (homa-ir) index, total cholesterol, low-density lipoprotein, high-density lipoprotein, and uric acid. furthermore, the perceived quality of life was investigated through the 36-items short form health survey (sf36) questionnaire.


Eligibility criteria:
inclusion criteria: * bmi between 30-45 kg/m2 * healthy subjects * regular meal consumption * no celiac disease * no menopause woman exclusion criteria: * with a bmi \ 45 kg/m2 * having diabetes, hepatic or kidney diseases * having an eating disorder * having celiac disease * menopause woman

Keywords: mediterranean diet bmi weight loss pasta obesity
coureur study myocardial inflammation in cyclist part 1

Conditions: Myocardial Inflammation

Summary: the study will evaluate myocardial inflammation in cyclists after high intense and sustained exercise. our hypothesis is that strenuous exercise in recreational cyclists may be associated with myocardial inflammation. myocardial fibrosis in asymptomatic athletes is associated with life-threatening arrhythmic events and sudden death. although myocarditis seems to be the most likely underlying cause, it remains unclear if strenuous and sustained physical exercise can cause myocardial inflammation with development of myocyte necrosis and possibly myocardial fibrosis in athletes. nineteen recreational cyclists performing "l'etape du tour (edt) de france" a cycling ride (175 km, 3600 m of positive altitude difference) on july 4 2021 will be included in this study. in part 1 of the study, each participant will complete a detailed questionnaire detailing their training history and an echocardiography at rest will be performed. all participants will have exercise testing approximately 1 week before the edt stage to set aerobic and anaerobic gas exchange thresholds, as well as vo2max.


Eligibility criteria:
inclusion criteria: * recreational cyclists performing the 'étape du tour (edt) de france 2021 ride exclusion criteria: * presence of pre-existing cardiovascular or pulmonary diseases, hypertension, diabetes, peripheral vascular diseases, any inflammatory or auto-immune diseases and the intake of anti-inflammatory drugs.
assessment of the state of health, quality of life and expectations of patients with hereditary angioedema

Conditions: Hereditary Angioedema

Summary: 8 years after the establishment of the therapeutic education program and 14 years after the creation of the national reference center for angioedemas (creak), it is necessary to make an inventory in 2021 on the disease experienced by the patient with an assessment the needs and expectations of hae patients. this assessment would make it possible to see the evolution of these needs and to adjust the price for the overall cost of children and adults in france. it may also allow a comparison of the requests expressed during a similar survey in another french-speaking region such as quebec. main objective is to know the needs and the current satisfaction of the needs, with regard to the disease and the treatment of the targeted patients of hereditary angioedema (hae)


Eligibility criteria:
inclusion criteria: * patient with hae with or without c1 inhibitor deficiency * patient over 15 or parents of a child under 15 with hae exclusion criteria: * patient opposed to the use of their data or refusing to answer the questionnaire * adult patients protected by law
intensive glycemic control and skeletal health study

Conditions: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia; Hypertension; Diabetes Mellitus; Coronary Disease

Summary: the purpose of the accord-bone study is to investigate the effects of intensive glycemic control for type 2 diabetes (in accord participants) on factors related to bone health, including, fractures, falls, and bone mineral density.

recent studies have established that type 2 diabetes is a risk factor for fractures, particularly of the hip, shoulder and foot. additionally, type 2 diabetes is associated with a 50-60% increase in the risk of falling. the higher risk of fracture associated with type 2 diabetes is an important health burden for these patients. more frequent falls and perhaps reduced bone strength in those with diabetes are thought to be key contributing factors. the best approach to preventing fractures in type 2 diabetes is not yet understood. there is observational evidence to support our hypothesis that better glycemic control will preserve bone and reduce falls and fractures. the accord-bone study provides a unique opportunity to determine whether intensive glycemic control will prevent fractures, falls, and bone loss in older diabetic adults, which may lead to improved treatment and prevention in the future.

Eligibility criteria:
inclusion criteria: * fulfills criteria for inclusion in the accord main trial * must have been randomized into the accord study and be a participant from the five ccns in the accord-bone ancillary study. exclusion criteria: * fulfills criteria for exclusion in the accord main trial

Keywords: diabetes mellitus fracture falls height loss
efficacy and safety study of spl7013 gel to prevent the recurrence of bacterial vaginosis (bv)

Conditions: Bacterial Vaginosis

Summary: a double-blind, phase 3 study to determine the efficacy of spl7013 gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of bv in women with a history of recurrent bv.

eligible participants, with both a history of recurrent bv and a current episode of bv, will receive a seven-day course of oral metronidazole. participants who are successfully treated for their bv, and continue to be eligible, will be randomly assigned to receive either 1% spl7013 gel or placebo gel on alternate days at bed-time for 16 consecutive weeks. the primary endpoint will be determined at the conclusion of this 16 week treatment phase. participants who experience a bv recurrence will be considered to have completed the study. such participants will receive bv treatment in line with local practice and will not attend any further study visits. participants who successfully reach week 16 without a bv recurrence will enter a 12-week follow-up phase to week 28. participants will attend a study visit at 4-weekly intervals throughout the duration of the study to week 28 (or up to the point of bv recurrence) to assess recurrence of bv and adverse events.

Eligibility criteria:
inclusion criteria: * current active episode of bv (diagnosis defined as: at least 3 of the 4 amsel criteria; nugent score of at least 4; presence of bv-related symptoms) * history of recurrent bv (at least 3 episodes in previous year including current episode) * using an effective method of contraception exclusion criteria: * test positive for a sexually transmitted infection * presence of genital herpes simplex virus (hsv) lesions or human papilloma virus (hpv) lesions requiring treatment * abnormal pelvic exam, including presence of other vaginal or urinary tract infections * pregnancy
comparing effects of two fixed combinations ophthalmic solutions on ocular blood flow

Conditions: Glaucoma

Summary: a 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.


Eligibility criteria:
inclusion criteria: 1. age: 30 years or older. 2. primary open-angle glaucoma (poag) or ocular hypertensive in at least one eye. 3. best corrected visual acuity at least 20/40 in at least one eye. exclusion criteria: 1. history of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy. 2. history of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis). 3. history or signs of intraocular trauma. 4. any abnormality preventing reliable applanation tonometry. 5. current use of any ophthalmic or systemic steroid which may interfere with this investigation. 6. severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.
assessment of maternal and fetal serum biomarkers in women with pre-eclampsia

Conditions: Inflammatory Markers; Preeclampsia Severe; Preeclampsia Mild; Umbilical Cord Issue; Inflammatory Response; Serum Seromucoid in Pregnancy; Protein-bound Hexose in Preeclampsia

Summary: the findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

preeclampsia is a pregnancy-specific hypertension illness that is characterized by widespread maternal endothelial dysfunction and appears to be a systemic syndrome that originates in the placenta. through binding to and blocking the interaction of placental growth factor (plgf) and vascular endothelial growth factor (vegf) with their receptors flt1, soluble fms-like tyrosine kinase (sflt1) functions as an antagonist of these growth factors. most seromucoid and protein-bound hexose are released during an acute phase and are inflammatory glycoproteins. hepatocytes in the liver, which are highly sensitive to stress, increase and leak into the bloodstream during any disease state. it is a time when the placenta demands more vascular development. in order to identify and explain the differences in sflt-1, vegf, plgf levels, and inflammatory biomarker responses. current study will investigate the differences in blood level of sflt-1, vegf, plgf, seromucoid and protein-bound hexose inflammatory biomarkers between those with pe (cases) and healthy pregnant women (controls).

Eligibility criteria:
inclusion criteria: * age group 18-45 years * gestational age of 26-41 weeks at the time of diagnosis for preeclampsia * delivered vaginally or abdominally * being of any parity (para 1 and more) * pregnancy being singleton or multiple pregnancies * willingness to provide informed consent exclusion criteria: * pregnant woman having chronic hypertension * having diabetes mellitus * the lady on medications that can affect inflammatory markers or blood pressure * pregnant with fetal anomalies * refused to involve in the research
comparation of chidamide plus vrd (bortezomib, lenalidomide, dexamethasone) with vrd regimen for primary high-risk multiple myeloma patients

Conditions: Multiple Myeloma

Summary: in the phase i trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase ii trial, the safety and efficacy of chidamide+vrd will be compared with that of vrd regimen.

in the phase i trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, which will be determined by efficacy and safety profiles of the patients; afterward, the optimal dosage of chidamide will be combined with vrd regimen, patients will be randomly assigned to chidamide+vrd group or vrd group, and their efficacy and safety will be compared.

Eligibility criteria:
inclusion criteria: * 1.diagnosed as multiple myeloma, and has one of the above: 1. high risk karyotype, such as 17p-，t（4；14），t（14；16），t（14；20）或1q gain,1p-, double hit myeloma, triple hit myeloma, etc; 2. riss-3; 3. igd/ige mm; 4. with measurable extra-medullary plasmacytoma; 5. flowcytometry showed peripheral blood plasma cell ≥0.165%； * 2.secretory mm should have measurable markers, including: 1. specific m protein value (≥5g/l)； 2. and/or involved flc ≥100mg/l； 3. and/or measurable extramedullary foci (diameter\>1cm on ct); * 3.age≥18 years, male or female; * 4.ecog 0-2 points, with life expectance ≥3 months; ga score \<2; * 5.alt/ast level \<2.5 times of the maximum of normal range; total bilirubin\<1.5 times of normal maximum； * 6.neutrophil count≥1.5×109/l, platelet count≥50×109/l; * 7.egfr≥40ml/min，except in the case of myeloma-related nephropathy; * 8.normal left ventricular ejaculation rate, nyha stage 1, pulmonary function gold stage 1; * 9.willing to accept the possibility of potential adverse events and efficacy observation by the investigators; * 10.being able to understand and signing the written consent, which should be signed prior to any procedure of the trial. exclusion criteria: * 1.with ≥2 degree of peripheral neuropath or with pain; * 2.having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed; * 3.with severe pulmonary/cardiac disfunction (including history of qt interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction; * 4.patients in pregnancy or lactation; * 5.allergic constitution or being allergic to any drug within the regimen of the trial; * 6.with uncontrolled mental diseases; * 7.with active infection; * 8.with non-myeloma-associated acute renal dysfunction; * 9.with active hepatitis; * 10.hiv positive; * 11.history of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma; * 12.with other conditions that the investigators think unfit for the trial.